A post-hoc analysis of two clinical trials compared continuous calorie restriction with early time-restricted eating in adults with type 2 diabetes and overweight or obesity over three months. Both ...

According to recent data, patients initiating semaglutide had a substantially greater risk of developing NAION versus those starting SGLT2 inhibitors. Although rare, semaglutide initiation can lead to ...

Women with type 2 diabetes who started on metformin rather than a sulfonylurea had roughly 30 percent lower odds of dying before age 90, according to a new study built on decades of data from the ...

Diabetes and kidney disease are major risk factors for heart disease, yet many cases are undiagnosed. In addition, a consumer survey done last fall suggests that most people don't realize that their ...

Taking magnesium and berberine together may lower blood sugar, but there is currently limited evidence supporting their ...

They found that 1.4 years after these medications were stopped, the cardiometabolic markers that they looked at, such as ...

New dedicated spaces offer condition-specific education, peer support, and meaningful engagement opportunities for ...

Eli Lilly and Company LLY is one of the two clear leaders in the rapidly expanding diabetes and obesity treatment market, ...

Some patients in a clinical trial of one new drug lost so much weight that they became concerned and dropped out.

A 2025 study suggests that metformin — a widely used treatment for type 2 diabetes — may also be associated with longer life ...

GLP-1 receptor agonists, originally developed for type 2 diabetes, are now witnessing soaring demand for weight management, with drugs like Ozempic gaining widespread popularity, particularly on ...

NICE recommends SGLT-2 inhibitors with metformin at diagnosis, citing major cardiovascular, renal, and mortality benefits.